PTPRC and neoplasm: In our study, the presence of infiltrating CD45+ cells in regressing tumor masses undergoing CTX + ACT/IS but not in resilient tumors receiving single treatments, strongly suggests that the immune-enhancing effect of CTX pretreatment followed by ACT/IS may be explained, at least in part, by an increase in the presence of antigen-specific T cells at the tumor site.